ACAD Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of 13.09% compared to ACADIA Pharmaceuticals's net margin of -49.65%. ACADIA Pharmaceuticals's return on equity of 27.32% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

ACADIA Pharmaceuticals has a consensus price target of $24.95, signalling upside risk potential of 35.51%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 503.14%. Given that NovaBay Pharmaceuticals has higher upside potential than ACADIA Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals has a beta of 0.374, which suggesting that the stock is 62.624% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

ACADIA Pharmaceuticals quarterly revenues are $250.4M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. ACADIA Pharmaceuticals's net income of $32.8M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 23.60x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 3.29x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 13.09% compared to ACADIA Pharmaceuticals's net margin of 25.23%. ACADIA Pharmaceuticals's return on equity of 27.32% beat Pfizer's return on equity of 4.63%.

ACADIA Pharmaceuticals has a consensus price target of $24.95, signalling upside risk potential of 35.51%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.83%. Given that ACADIA Pharmaceuticals has higher upside potential than Pfizer, analysts believe ACADIA Pharmaceuticals is more attractive than Pfizer.

ACADIA Pharmaceuticals has a beta of 0.374, which suggesting that the stock is 62.624% less volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.

ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.32% to investors and pays a quarterly dividend of $0.42 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

ACADIA Pharmaceuticals quarterly revenues are $250.4M, which are smaller than Pfizer quarterly revenues of $17.7B. ACADIA Pharmaceuticals's net income of $32.8M is lower than Pfizer's net income of $4.5B. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 23.60x while Pfizer's PE ratio is 35.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 3.29x versus 2.55x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of 13.09% compared to ACADIA Pharmaceuticals's net margin of -2357.27%. ACADIA Pharmaceuticals's return on equity of 27.32% beat Palatin Technologies's return on equity of --.

ACADIA Pharmaceuticals has a consensus price target of $24.95, signalling upside risk potential of 35.51%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1140.88%. Given that Palatin Technologies has higher upside potential than ACADIA Pharmaceuticals, analysts believe Palatin Technologies is more attractive than ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals has a beta of 0.374, which suggesting that the stock is 62.624% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

ACADIA Pharmaceuticals quarterly revenues are $250.4M, which are larger than Palatin Technologies quarterly revenues of $350K. ACADIA Pharmaceuticals's net income of $32.8M is higher than Palatin Technologies's net income of -$7.8M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 23.60x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 3.29x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Verastem has a net margin of 13.09% compared to ACADIA Pharmaceuticals's net margin of -82.56%. ACADIA Pharmaceuticals's return on equity of 27.32% beat Verastem's return on equity of -120.71%.

ACADIA Pharmaceuticals has a consensus price target of $24.95, signalling upside risk potential of 35.51%. On the other hand Verastem has an analysts' consensus of $11.86 which suggests that it could grow by 69.39%. Given that Verastem has higher upside potential than ACADIA Pharmaceuticals, analysts believe Verastem is more attractive than ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals has a beta of 0.374, which suggesting that the stock is 62.624% less volatile than S&P 500. In comparison Verastem has a beta of 0.237, suggesting its less volatile than the S&P 500 by 76.284%.

ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. Verastem pays out -- of its earnings as a dividend.

ACADIA Pharmaceuticals quarterly revenues are $250.4M, which are larger than Verastem quarterly revenues of $10M. ACADIA Pharmaceuticals's net income of $32.8M is higher than Verastem's net income of -$24M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 23.60x while Verastem's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 3.29x versus -- for Verastem. Usually stocks with elevated PS ratios are considered overvalued.